Sitemap
September 28, 2019 Articles
Filter by Available Specialty
- Addition of olaparib to maintenance bevacizumab significantly improves PFS in ovarian cancer
- Algorithm using EMR data may better predict mortality in polytrauma patients
- Benefit of nonculprit PCI for STEMI consistent regardless of timing: COMPLETE
- Cardiac neuromodulation therapy drives reduction in BP
- Cediranib plus olaparib effective, safe for recurrent, platinum-resistant ovarian cancer
- COAPT: MitraClip benefit maintained at 3 years in HF, mitral regurgitation
- Department of Defense awards $10 million to Cedars-Sinai for pancreatic disease research
- Dispelling the myths of early RA
- EXCEL: PCI ‘acceptable revascularization modality’ for left main CAD at 5 years
- Front-line osimertinib improves OS in EGFR-mutated lung cancer
- Greater operator, hospital mitral valve surgery volume tied to reduced mortality, more repair
- Immunotherapy combination improves OS compared with chemotherapy in lung cancer subset
- Minimizing prednisone, nephrotoxic agents crucial for lupus nephritis outcomes
- Niraparib significantly extends PFS in newly diagnosed advanced ovarian cancer
- PARTNER 2A: TAVR remains similar to surgery for 5-year outcomes in intermediate-risk population
- Pharmaceutical company develops inhaled endocrine therapies
- Reconsidering, retiring the controversial ‘lupus headache’
- Study adds evidence of sexual exchange of G. vaginalis among women
- Surgical exploration ‘highly recommended’ after induction chemotherapy for locally advanced pancreatic cancer
- Transseptal access confers lower mortality in mitral valve-in-valve repair
- VIDEO: New frontier of biocompatible corneal inlays for presbyopia
- VIDEO: Vancomycin powder in fracture surgery does not produce more difficult infections